Neparvis (Valsartan, Sacubitril)

Neparvis (sacubitril/valsartan) is indicated for cardiovascular conditions that involve the renin‑angiotensin‑neprilysin system, primarily heart failure and hypertension.

• Heart failure: improves survival and reduces hospitalizations in adults with reduced ejection fraction heart failure.
• Hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension.
• Cardiovascular remodeling: attenuates pathological cardiac remodeling associated with chronic heart failure, supporting long‑term cardiac function.
• Post‑myocardial infarction: may aid recovery in patients with left ventricular dysfunction after myocardial infarction.

• Neparvis combines sacubitril, a neprilysin inhibitor, with valsartan, an angiotensin II type 1 receptor blocker. Sacubitril prevents the breakdown of natriuretic peptides, bradykinin and adrenomedullin, enhancing vasodilation, natriuresis and inhibition of fibrosis. Valsartan blocks angiotensin II‑mediated vasoconstriction, aldosterone secretion and sympathetic activation. The dual action simultaneously augments beneficial peptide pathways while suppressing the renin‑angiotensin system, resulting in improved cardiac hemodynamics and reduced pathological remodeling.

Neparvis may be associated with a range of adverse reactions, which are categorized by frequency and clinical significance.

Common Side Effects

• Dizziness: transient light‑headedness, especially after the first dose.
• Hypotension: symptomatic low blood pressure, may require dose adjustment.
• Cough: dry or productive cough occurring during therapy.
• Hyperkalemia: elevated serum potassium levels, monitor regularly.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue or airway, requires immediate medical attention.
• Acute kidney injury: sudden decline in renal function, monitor creatinine.
• Hepatic enzyme elevation: increased ALT/AST, assess liver function tests.

When prescribing Neparvis, clinicians should consider several precautionary measures to ensure safe and effective use.

• Blood pressure monitoring: check baseline and periodic readings to avoid symptomatic hypotension.
• Renal function assessment: evaluate serum creatinine and eGFR before initiation and during therapy.
• Serum potassium surveillance: monitor potassium levels, especially in patients on potassium‑sparing agents.
• Contra‑indication with ACE inhibitors: ensure a 36‑hour washout period when switching from ACE inhibitors to avoid angioedema.
• Hepatic impairment caution: use with care in patients with moderate liver disease, adjusting dose if necessary.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and excessive heat.

Neparvis interacts with several medicines; understanding the interaction potential helps prevent adverse events.

Major Interactions (Avoid)

• ACE inhibitors or aliskiren: concurrent use increases risk of angioedema and renal dysfunction.
• Potassium‑sparing diuretics (e.g., spironolactone): may cause severe hyperkalemia.
• NSAIDs: can diminish antihypertensive effect and worsen renal function.
• Other neprilysin inhibitors: additive inhibition may lead to excessive bradykinin accumulation.

Moderate Interactions (Monitor Closely)

• Conventional diuretics: may potentiate hypotensive effects, requiring dose titration.
• Antihypertensive agents (beta‑blockers, calcium channel blockers): additive blood pressure lowering.
• Lithium: reduced clearance may raise lithium levels, necessitating monitoring.
• Rifampin or other CYP3A4 inducers: may lower valsartan plasma concentrations.